SECTION 1 : IDENTIFICATION

Product Name: Linezolid Injection
Product Use/Restriction: Antibacterial Agent
Manufacturer Name: Fresenius Kabi Norge AS
Address: Svinestundsveien 80
P. O. Box 430
1753 Halden, Norway
General Phone Number: +47-69-211100
General Fax Number: +47-69-211101
Distributor Name: Fresenius Kabi USA, LLC
Address: Three Corporate Drive
Lake Zurich, Illinois 60047
General Phone Number: (847) 550-2300
Customer Service Phone Number: (888) 386-1300
Health Issues Information: (800) 551-7176
SDS Creation Date: September 24, 2015
SDS Revision Date: March 18, 2016

SECTION 2 : HAZARD(S) IDENTIFICATION

GHS Pictograms:

Signal Word: DANGER.
GHS Class: Specific Target Organ Toxicity - STOT Repeated exposure RE category 1 (Oral, Blood, Peripheral and Optic Nervous system). Reproductive toxicity. Effects on or via lactation.
Hazard Statements: Causes damage to organs through prolonged or repeated exposure. May cause harm to breast-fed children.
Precautionary Statements: Obtain special instructions before use. Do not breathe dust/fume/gas/mist/vapours/spray. Avoid contact during pregnancy and while nursing. Wash hands thoroughly after handling. Do not eat, drink or smoke when using this product. IF exposed or concerned: Get medical advice/attention. Get medical advice/attention if you feel unwell. Dispose of contents/container in accordance with Local, State, Federal and Provincial regulations.

Emergency Overview: This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.

Route of Exposure: Inhalation Ingestion Eye contact Skin Absorption. Injection.

Potential Health Effects:
Eye: Contact with eyes may cause irritation.
Skin: May cause skin irritation.
Inhalation: May cause irritation of respiratory tract.
Ingestion: May cause irritation.

Signs/Symptoms: Adverse reactions from therapeutic doses include: headache, nausea, diarrhea, vomiting and anemia.

Aggravation of Pre-Existing Conditions: Linezolid is contraindicated for use in patients who have known hypersensitivity to linezolid or any of the other product components. Linezolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g., phenelzine, isocarboxazid) or within two weeks of taking any such medicinal product.

SECTION 3 : COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>CAS#</th>
<th>Ingredient Percent</th>
<th>EC Num.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linezolid</td>
<td>165800-03-3</td>
<td>2 mg/mL</td>
<td></td>
</tr>
<tr>
<td>Dextrose, USP</td>
<td>50-99-7</td>
<td>50.24 mg/mL</td>
<td></td>
</tr>
<tr>
<td>Sodium citrate, USP</td>
<td>68-04-2</td>
<td>1.64 mg/mL</td>
<td></td>
</tr>
</tbody>
</table>
SECTION 4 : FIRST AID MEASURES

Eye Contact: Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of the eyes by separating the eyelids with fingers. Get immediate medical attention.

Skin Contact: Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing contaminated clothing and shoes. Get medical attention if irritation develops or persists.

Inhalation: If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained personnel. Seek immediate medical attention.

Ingestion: If conscious, flush mouth out with water immediately. Call a physician or poison control center immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person.

Other First Aid: For Adverse Event Information, please call (800) 551-7176.

SECTION 5 : FIRE FIGHTING MEASURES

Flash Point: Not established.
Flash Point Method: Not established.
Auto Ignition Temperature: Not established.
Lower Flammable/Explosive Limit: Not established.
Upper Flammable/Explosive Limit: Not established.
Fire Fighting Instructions: Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible, contain fire run-off water.

Extinguishing Media: Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires involving this material. Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Protective Equipment: As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent) and full protective gear.

Hazardous Combustion Byproducts: Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of combustion.

SECTION 6 : ACCIDENTAL RELEASE MEASURES

Personal Precautions: Evacuate area and keep unnecessary and unprotected personnel from entering the spill area. Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as listed in Section 8.

Environmental Precautions: Avoid runoff into storm sewers, ditches, and waterways.

Methods for containment: Contain spills with an inert absorbent material such as soil, sand or oil dry.

Methods for cleanup: Absorb spill with inert material (e.g., dry sand or earth), then place in a chemical waste container. After removal, flush spill area with soap and water to remove trace residue.

SECTION 7 : HANDLING and STORAGE

Handling: When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes. Use with adequate ventilation. Use only in accordance with directions.

Storage: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light (Linezolid is sensitive to light). It is recommended that the infusion bags be kept in the overwrap until ready to use. Protect infusion bags from freezing.

Work Practices: Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower.

Hygiene Practices: Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist.

SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

Engineering Controls: General ventilation is sufficient if this product is being used in a controlled medical setting (clinic, hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended exposure limits.
Eye/Face Protection: Chemical splash goggles. Wear a face shield also when splash hazard exist.

Skin Protection Description: Protective laboratory coat, apron, or disposable garment recommended.

Hand Protection Description: Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data. Nitrile rubber or natural rubber gloves are recommended.

Respiratory Protection: No personal respiratory protective equipment is normally required when this product is being used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site (http://www.cdc.gov/niosh/npptl/topics/respirators/) for a list of respirator types and approved suppliers.

Other Protective: Consult with local procedures for selection, training, inspection and maintenance of the personal protective equipment.

EXPOSURE GUIDELINES

**Hydrochloric acid**

Guideline ACGIH: TLV-STEL: 2 ppm(ceiling.)
Guideline OSHA: OSHA PEL-STEL 5 ppm ceiling./Peak.

SECTION 9 : PHYSICAL and CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical State</td>
<td>Liquid</td>
</tr>
<tr>
<td>Color</td>
<td>Colorless to slightly yellow aqueous solution.</td>
</tr>
<tr>
<td>Odor</td>
<td>Odorless</td>
</tr>
<tr>
<td>Boiling Point</td>
<td>Not established</td>
</tr>
<tr>
<td>Melting Point</td>
<td>177 - 182 °C</td>
</tr>
<tr>
<td>Specific Gravity</td>
<td>Not established</td>
</tr>
<tr>
<td>Solubility</td>
<td>Insoluble in water</td>
</tr>
<tr>
<td>Vapor Density</td>
<td>Not established</td>
</tr>
<tr>
<td>Vapor Pressure</td>
<td>Not established</td>
</tr>
<tr>
<td>Percent Volatile</td>
<td>Not established</td>
</tr>
<tr>
<td>Evaporation Rate</td>
<td>Not established</td>
</tr>
<tr>
<td>pH</td>
<td>Not established</td>
</tr>
<tr>
<td>Flash Point</td>
<td>Not established</td>
</tr>
<tr>
<td>Flash Point Method</td>
<td>Not established</td>
</tr>
<tr>
<td>Auto Ignition Temperature</td>
<td>Not established</td>
</tr>
<tr>
<td>VOC Content</td>
<td>Not established</td>
</tr>
</tbody>
</table>

SECTION 10 : STABILITY and REACTIVITY

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical Stability</td>
<td>Stable under normal temperatures and pressures.</td>
</tr>
<tr>
<td>Hazardous Polymerization</td>
<td>Not reported</td>
</tr>
<tr>
<td>Conditions to Avoid</td>
<td>Excessive heat may cause decomposition.</td>
</tr>
</tbody>
</table>

SECTION 11 : TOXICOLOGICAL INFORMATION

**Linezolid**

Reproductive Toxicity: Linezolid did not affect the fertility or reproductive performance of adult female rats. It reversibly decreased fertility and reproductive performance in adult male rats when given at doses ≥ 50 mg/kg/day, with exposures approximately equal to or greater than the expected human exposure level (exposure comparisons are based on AUCs). The reversible fertility effects were mediated through altered spermatogenesis. Affected spermatids contained abnormally formed and oriented mitochondria and were nonviable. Epithelial cell hypertrophy and hyperplasia in the epididymis was observed in conjunction with decreased fertility. Similar epididymal changes were not seen in dogs. (FDA Professional Monograph).

Teratogenicity: Linezolid was not teratogenic in mice, rats, or rabbits at exposure levels 6.5-fold (in mice), equivalent to (in rats), or 0.06-fold (in rabbits) the expected human exposure level, based on AUCs.

Other Toxicological Information: There are no data on the excretion of linezolid into human milk. Linezolid and its metabolites are excreted into rat milk, at concentrations similar to those in maternal plasma. The manufacturer recommends that caution be used when linezolid is administered to nursing women.

**Dextrose, USP**

Ingestion: Oral - Rat LD50 - Lethal dose, 50 percent kill: 25800 mg/kg [Behavioral-Coma Lungs, Thorax, or Respiratory-Cyanosis Gastrointestinal - Hypermotility, diarrhea] (RTECS)

**Citric acid, USP**

Eye: Administration into the eye - Rabbit Standard Draize test: 750 ug/24H [Severe] (RTECS)

Skin: Administration onto the skin - Rabbit Standard Draize test: 500 mg/24H [mild]
Ingestion:
Oral - Rat LD50 - Lethal dose, 50 percent kill: 3 gm/kg [Details of toxic effects not reported other than lethal dose value]
Oral - Rat LD50 - Lethal dose, 50 percent kill: 11700 mg/kg [Behavioral - Ataxia Cardiac-Change in rate Lungs, Thorax, or Respiration - Respiratory depression] (RTECS)

Sodium hydroxide:
Eye:
Administration into the eye - Rabbit Standard Draize test: 400 ug [Mild]
Administration into the eye - Rabbit Standard Draize test: 1 % [Severe]
Administration into the eye - Rabbit Standard Draize test: 50 ug/24H [Severe]
Administration into the eye - Rabbit Rinsed with water: 1 mg/30S [Severe] (RTECS)

Skin:
Administration onto the skin - Rabbit Standard Draize test.: 500 mg/24H

Ingestion:
Oral - Rabbit LD50: 500 mg/kg [Details of toxic effects not reported other than lethal dose value]

Hydrochloric acid:
Eye:
Administration into the eye - Rabbit Rinsed with water: 5 mg/30S [Mild] (RTECS)

Skin:
Administration onto the skin - Human Standard Draize test.: 4 %/24H (RTECS)

Inhalation:
Inhalation - Rat LC50 - Lethal concentration, 50 percent kill: 3124 ppm/1H [Sense Organs and Special Senses (Olfaction) - effect, not otherwise specified Sense Organs and Special Senses (Eye)-Iritis]
Inhalation - Rat LC50 - Lethal concentration, 50 percent kill: 45000 mg/m3/5M [Lungs, Thorax, or Respiration - Acute pulmonary edema]
Inhalation - Rat LC50 - Lethal concentration, 50 percent kill: 8300 mg/m3/30M [Lungs, Thorax, or Respiration - Acute pulmonary edema]
Inhalation - Rat LC50 - Lethal concentration, 50 percent kill: 60938 mg/m3/5M [Lungs, Thorax, or Respiration - Acute pulmonary edema]
Inhalation - Rat LC50 - Lethal concentration, 50 percent kill: 7004 mg/m3/30M [Lungs, Thorax, or Respiration - Acute pulmonary edema]
Inhalation - Rat LC50 - Lethal concentration, 50 percent kill: 3700 ppm/30M [Details of toxic effects not reported other than lethal dose value] (RTECS)

Ingestion:
Oral - Rabbit LD50: 900 mg/kg [Details of toxic effects not reported other than lethal dose value]

SECTION 12 : ECOLOGICAL INFORMATION
Ecotoxicity: No ecotoxicity data was found for the product.
Environmental Stability: No environmental information found for this product.

SECTION 13 : DISPOSAL CONSIDERATIONS
Waste Disposal: Dispose of in accordance with Local, State, Federal and Provincial regulations.

SECTION 14 : TRANSPORT INFORMATION
DOT Shipping Name: Not Regulated.
DOT UN Number: Not Regulated.
IATA Shipping Name: Non regulated.
IATA UN Number: Non regulated.
IMDG UN Number : Non regulated.
IMDG Shipping Name : Non regulated.

SECTION 15 : REGULATORY INFORMATION
Linezolid:
TSCA Inventory Status: Listed
Canada DSL: Listed
Dextrose, USP:
TSCA Inventory Status: Listed
Canada DSL: Listed
Sodium citrate, USP:
TSCA Inventory Status: Listed
Canada DSL: Listed
Citric acid, USP:
TSCA Inventory Status: Listed
Canada DSL: Listed
Sodium hydroxide:
TSCA Inventory Status: Listed

Product: Linezolid Injection | Manufacturer: Fresenius Kabi Norge AS | Revision:03/18/2016, Version:0
Page 4 of 5
Hydrochloric acid

TSCA Inventory Status: Listed

SARA:
EPCRA - 40 CFR Part 372 - (SARA Title III) Section 313 Listed Chemical.

Section 302 EHS:
EPCRA (SARA Title III) Section 302 (40 CFR Part 355) Extremely Hazardous Substances (EHS) Threshold Planning Quantity (TPQ) in pounds.: 500 Lbs.

Section 304 RQ:
EPCRA (SARA Title III) Section 304 Extremely Hazardous Substances (EHS) Reportable Quantities (RQ) in pounds.: 5,000 Lbs.

Canada DSL: Listed

Canada IDL:
Identified under the Canadian Hazardous Products Act Ingredient Disclosure List: 0.1%.845(502)

SECTION 16 : ADDITIONAL INFORMATION

HMIS Ratings:

HMIS Health Hazard: 1
HMIS Fire Hazard: 1
HMIS Reactivity: 1
HMIS Personal Protection: X

SDS Creation Date: September 24, 2015
SDS Revision Date: March 18, 2016

Disclaimer:
The information contained herein pertains to this material. It is the responsibility of each individual party to determine for themselves the proper means of handling and using these materials based on their purpose and intended use. Fresenius-Kabi assumes no liability resulting from the use of or reliance upon the information contained in this material safety data sheet. This material safety data sheet does not constitute the guaranty or specifications of the product.

Copyright © 1996-2015 Actio Corporation. All Rights Reserved.